The findings underscore the clinical applicability of IL-23 inhibition as a targeted strategy for PsA patients, particularly those with moderate-to-severe joint involvement, extensive psoriasis, or inadequate response to existing biologic therapies. This evidence concerns the gene IL37 and psoriasis.